Related Experiment Videos
Erythrocyte complement receptor type 1 in non-SLE rheumatic diseases
1Department of Internal Medicine, Kaohsiung Medical College, Taiwan, Republic of China.
Insights
Erythrocyte complement receptor type 1 (CR1) levels are significantly lower in patients with immune-mediated rheumatic diseases like ankylosing spondylitis and rheumatoid arthritis. CR1 levels did not correlate with disease activity in AS or RA, but showed a negative association with rheumatoid factor titer in RA.
Area of Science:
- Immunology
- Rheumatology
- Clinical Medicine
Background:
- Erythrocyte complement receptor type 1 (CR1) plays a role in immune complex clearance.
- Alterations in CR1 levels may be associated with rheumatic diseases.
Purpose of the Study:
- To measure erythrocyte CR1 levels in patients with various rheumatic diseases.
- To evaluate the clinical significance of erythrocyte CR1 in ankylosing spondylitis (AS) and rheumatoid arthritis (RA).
Main Methods:
- Erythrocyte CR1 levels were quantified in 37 healthy controls and 106 patients with rheumatic conditions.
- Statistical analyses were performed to compare CR1 levels and correlate them with clinical parameters.
Main Results:
- Significantly decreased erythrocyte CR1 levels were observed in patients with AS, juvenile rheumatoid arthritis, Sjögren's syndrome, and RA.
- No significant difference in CR1 levels was found in patients with gouty arthritis compared to controls.
- In RA patients, erythrocyte CR1 levels showed a negative association with rheumatoid factor titer but were not correlated with disease activity or severity.
Conclusions:
- Erythrocyte CR1 deficiency may be linked to immune-mediated rheumatic diseases.
- CR1 levels do not appear to directly reflect disease activity in AS or RA.
- Further research is warranted to explore the prognostic value of erythrocyte CR1 levels in RA.
Abstract:
An investigation was conducted to measure the levels of erythrocyte complement receptor type 1 (CR1) in patients with various rheumatic diseases other than systemic lupus erythematosus, and to evaluate the clinical significance of this receptor in patients with ankylosing spondylitis (AS) and rheumatoid arthritis (RA). Erythrocyte CR1 was measured in 37 normal controls and 106 patients with various rheumatic diseases. The levels of erythrocyte CR1 decreased significantly in patients with AS, juvenile rheumatoid arthritis, Sjögren's syndrome, and RA, while there was no statistical difference in levels of erythrocyte CR1 between normal controls and patients with gouty arthritis. This suggests that erythrocyte CR1 deficiency may occur in immune-mediated rheumatic diseases such as crystal-induced arthritis. In this study, we noted that the levels of erythrocyte CR1 were not related to the disease activity and severity of AS. The levels of erythrocyte CR1 were also not correlated with the clinical and laboratory parameters of disease activity in RA patients. However, there was a negative association between the levels of erythrocyte CR1 and titer of rheumatoid factor in RA patients. Further study is needed to determine whether or not the level of erythrocyte CR1 is related to prognosis in patients with RA.